.
Sign in | Register
Home | My Space | Post
Home » undefined
Disclaimer : The views expressed in the forum are the views of the user writing the post, and not that of moneycontrol.com. You agree, by accessing this forum, that moneycontrol.com bears no liability for any posts on this forum or, any losses suffered by following any advice posted on this forum. moneycontrol.com operates this real time, open, unmoderated, private forum for users to exchange information and to discuss various investing techniques. moneycontrol.com or, its personnel do not post anything, or vet the content posted, on this forum. moneycontrol.com reserves the right to deny service to anyone. You, and not moneycontrol.com, assume the entire cost and risk of any trading you choose to undertake. You are solely responsible for making your own investment decisions. If you choose to engage in such transactions with or without seeking advice from a licensed and qualified financial advisor or entity, then such decision and any consequences flowing therefrom are your sole responsibility.
undefined - Undefined - Follow Thread
Wockhardt is targetting a global market worth over 7 billion for Gram-negative infections. With over 8 million cUTI cases annually in the US and EU, Zaynich has the potential to become a blockbuster drug, if and when approved. Wockhardt is prioritising commercialisation of the drug on its own in the US, though it has not fully closed the doors for partnerships. The drug’s success could significantly boost Wockhard global footprint and revenue, given its strong presence in Europe and international markets. ( 226 days ago )
  StockGlory  63 followers
Rate :
Repost |  Mark Offensive
« Previous Next »
view comment
Stock Boarder Message
Active Topics
index | CRUDEOIL | SpiceJet | COPPER | Indosolar
Explore all topics
Boarder of the Day
amateurinvestor (91002 messages | 0 follower)
HOME
Moneycontrol Home
Font Size: S M L
Customer Support
© 2026 a Web18 Venture